Navigation Links
Transcriptase in Biological Technology

Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference

... novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human ... of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients" ... is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully ...

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

... data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including ... RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of ... candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study ...

Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting

... Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients ... most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for ...

Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology

... RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 ... most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. ...

Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences

... data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral ... Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. ...

FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy

... INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced ... that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness. As with other HIV ...

Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results

... clinical studies of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV, in August of 2007; -- Presentation of four ... year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase ...

A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis

... capture (NASBA-EOC). The VDS technology has an advantage of not requiring the use of specialized equipment; VetDetect utilizes real-time reverse transcriptase polymerase chain reaction (RT-PCR) and VetScreen employs the conventional gel-based RT-PCR technique. All three platforms are highly sensitive and ...

Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)

... Tablets are the generic version of Gilead Sciences Inc.'s Truvada(R) Tablets. Truvada(R) is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI or "nuke") family and is used in combination with other medications to control HIV infection. Patients often use second-line ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... Business Highlights Idenix successfully completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had ...

Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results

... approximately $60.1 million. 2008 Year-to-Date Business Highlights -- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving ...

Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission

... cells, preventing infection. Finally, the third and most potent activity of the product will prevent the critical action of the virus-encoded reverse transcriptase inside the cell. Key features of the development program include the formulation of the product for delivery as gels or intravaginal rings, ...

Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results

... 2008 Year-to-Date Business Highlights -- Idenix has reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of ...

Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout

... in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our ...

Craig Johnson Joins Ardea Biosciences' Board of Directors

... in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, ...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008

... in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment ...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... in the first quarter of 2008 from $120 million in the same period in 2007. -- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, increased 21% to $273 million in the first quarter of 2008 from $226 million in the same period in 2007. ...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

... "A Novel NNRTI Class with Potent Anti-HIV Activity against NNRTI-Resistant Viruses." About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may ...

Ardea to Present at Cowen and Company's 28th Annual Health Care Conference

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts

... across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase 2b trial and the Phase 3 program has been initiated. Avexa ...

Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...

Ardea Biosciences Establishes Scientific Advisory Board for HIV Program

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...

Ardea Biosciences Announces $40 Million Private Placement

... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a ...

Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference

... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a ...

New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties

... The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...

Ardea Biosciences Announces Changes to Research Management

... The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...

Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs

... on what we believe is most critical to our future success -- building and advancing our pipeline." Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive ...

Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.

... on three or more compounds this year. These compounds include RDEA806 and lead compounds from our 900 series, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV, and RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and ...

RNA Amplification Just Got Better: MessageAmp II

... , an M-MLV reverse transcriptase specifically engineered to ... Figure 1. ArrayScript Reverse transcriptase Synthesizes Intact cDNA Products as ... Figure 2. ArrayScript Reverse transcriptase Produces up to Twice the aRNA Yield in MessageAmp ...

ArrayScript RT: Maximize Yields of Full-length cDNA

... have engineered a mutant form of M-MLV reverse transcriptase to improve production of full-length ... Figure 1. ArrayScript Reverse transcriptase Synthesizes Intact cDNA Products as ... Figure 2. ArrayScript Reverse transcriptase Produces up to Twice the cRNA Yield in ...

Use of Transcriptor Reverse Transcriptase in Microarray Analysis

... intensities shows that the Transcriptor Reverse transcriptase produced a major shift in the signal distribution ... that target labelling with Transcriptor Reverse transcriptase is highly reproducible and produces fewer outlier ... properties of Transcriptor Reverse transcriptase suggest that it will produce a labelled target ...

Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase

... Transcriptor Reverse transcriptase is a new recombinant reverse transcriptase (RT) expressed in E. coli. The enzyme has ... Transcriptor Reverse transcriptase has a broad dynamic detection range of 12 1.2 x ...

Transcriptor Reverse Transcriptase

... with the new Transcriptor Reverse transcriptase With the new ... RNA Transcriptor Reverse transcriptase is the product of choice to transcribe RNA ... inserts Transcriptor Reverse transcriptase will allow you to Get ...

RT-PCR procedures

... In the first step, reverse transcriptase produces first-strand cDNA in the ... the right combination of reverse transcriptase and thermostable DNA polymerase, two-step ... Finally, the thermoactive reverse transcriptase used in this procedure allow a high RT ...
Other Contents
(Date:7/23/2014)... risk warning for Yellowknife and surrounding area because of ... In the image taken by the Aqua satellite, ... Fire is an obvious health hazard, but the ... obvious and its effects are insidious. , The smoke ... structure, tires, waste or wood burning) is a mixture ...
(Date:7/23/2014)... Roughly 780 million people around the world have no ... Health Organization (WHO), 3.4 million people die from water-related ... the goal of making a contribution to solving this ... Wendelin Stark, head of the Functional Materials Laboratory, the ... developing a prototype. , "What makes our DrinkPure filter ...
(Date:7/23/2014)... Worldwide Innovative Networking in personalized cancer medicine, (the WIN ... at Thomas Jefferson University will be one ... of this prestigious group in the Tri-State Area. The ... innovative personalized medicine to the patient by forging collaborations ... "Our participation in the WIN consortium means Jefferson cancer ...
Breaking Biology News(10 mins):ETH student develops filter for clean water around the world 2New partnership brings more personalized cancer treatment to Philadelphia 2
(Date:7/23/2014)... and young adults living near Sellafield or Dounreay since ... developing cancer according to research published in the ... from the Childhood Cancer Research Group at the University ... between 1963 and 2006 among those who were under ... No difference was found in cancer incidence from 1991-2006 ...
(Date:7/23/2014)... 2014 A new study has uncovered ... ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive hysterectomies can ... woman’s body, Bernstein Liebhard LLP reports. The research, which ... the American Medical Association, looked at 36,000 women who ... U.S. hospitals from 2006 to 2012. Ninety-nine of the ...
(Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... -- Painful or itchy skin lesions could be a ... sometimes have multiple lesions that are suspicious looking, and ... concerns for non-melanoma skin cancers," study author Dr. Gil ... Medicine, said in a Temple University Health System news ... 268 patients who were confirmed to have skin cancer ...
(Date:7/23/2014)... Rich Dad® Education, a leader in financial education, is ... to support Habit for Humanity of Lee and Hendry Counties. ... be donated to Habitat for Humanity. Additionally, all the items ... Habitat for Humanity ReStore thrift store located at 31 Willis ... the highlights of the yard sale was a visit from ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2
Other TagsOther Tags